StreetInsider.com News Articles

Vaxil completes $140,000 private placement, names new director

Thu, 04 Dec 2025 07:00:17 -0500

Vaxil Bio Ltd. (TSX VENTURE: VXL) completed a non-brokered private placement raising gross proceeds of $140,000, according to a company statement. The biotech company sold 1,244,441 units at $0.1125 per unit, with each unit comprising one common share and one warrant exercisable at $0.15 until December 2, 2030.

The securities are subject to a hold period until April 3, 2026, under Canadian securities law. Vaxil paid $11,200 in finders' fees and issued 99,555 finders' warrants with terms identical to the unit warrants.

The company stated it plans to use net proceeds to explore strategic options beyond the healthcare sector to maximize shareholder

Vaxil completes $140,000 private placement, names new director

Thu, 04 Dec 2025 07:00:17 -0500

The company stated it plans to use net proceeds to explore strategic options beyond the healthcare sector to maximize shareholder

Vaxil completes $140,000 private placement, names new director

Thu, 04 Dec 2025 07:00:17 -0500

The company stated it plans to use net proceeds to explore strategic options beyond the healthcare sector to maximize shareholder

Vaxil completes $140,000 private placement, names new director

Thu, 04 Dec 2025 07:00:17 -0500

The company stated it plans to use net proceeds to explore strategic options beyond the healthcare sector to maximize shareholder

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private placement (see press release dated November 24, 2025) for gross proceeds of $140,000 (the "Private Placement"). Investors in the Private Placement subscribed for 1,244,441 units ("Units") at a price of $0.1125 per Unit. Each Unit consisted of one common share in the capital of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"),

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

Thu, 04 Dec 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

VAXIL revises private placement terms to raise up to $350,000

Mon, 24 Nov 2025 07:01:02 -0500

Vaxil Bio Ltd. (TSX VENTURE: VXL) announced revisions to its previously disclosed private placement offering, now targeting up to $350,000 in gross proceeds through the sale of 3,111,111 units priced at $0.1125 each.

Each unit consists of one common share and one share purchase warrant. The warrants allow holders to purchase additional shares at $0.15 per share for five years following the offering's completion.

The company expects to close the offering around December 4, 2025, subject to TSX Venture Exchange approval and other conditions. Net proceeds will support general corporate purposes.

Vaxil has agreed to pay finders a cash commission of up to

VAXIL revises private placement terms to raise up to $350,000

Mon, 24 Nov 2025 07:01:02 -0500

Each unit consists of one common share and one share purchase warrant. The warrants allow holders to purchase additional shares at $0.15 per share for five years following the offering's completion.

The company expects to close the offering around December 4, 2025, subject to TSX Venture Exchange approval and other conditions. Net proceeds will support general corporate purposes.

Vaxil has agreed to pay finders a cash commission of up to

VAXIL revises private placement terms to raise up to $350,000

Mon, 24 Nov 2025 07:01:02 -0500

Each unit consists of one common share and one share purchase warrant. The warrants allow holders to purchase additional shares at $0.15 per share for five years following the offering's completion.

The company expects to close the offering around December 4, 2025, subject to TSX Venture Exchange approval and other conditions. Net proceeds will support general corporate purposes.

Vaxil has agreed to pay finders a cash commission of up to

VAXIL revises private placement terms to raise up to $350,000

Mon, 24 Nov 2025 07:01:02 -0500

Each unit consists of one common share and one share purchase warrant. The warrants allow holders to purchase additional shares at $0.15 per share for five years following the offering's completion.

The company expects to close the offering around December 4, 2025, subject to TSX Venture Exchange approval and other conditions. Net proceeds will support general corporate purposes.

Vaxil has agreed to pay finders a cash commission of up to

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL) is pleased to announce that the Company, further to it's news release from October 29, 2025, that it has revised the terms of its previously announced offering and now intends to complete a non-brokered private placement on a commercially reasonable efforts basis (the "Offering") of up to 3,111,111 units ("Units") of the Company at a price of $0.1125 per Unit to raise gross proceeds of up to $350,000. Each

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

Vaxil Announces Update on Non-Brokered Private Placement

Mon, 24 Nov 2025 07:00:00 -0500

Not for distribution by US newswire or in United States

VAXIL announces $350,000 private placement offering

Wed, 29 Oct 2025 17:09:22 -0500

Vaxil Bio Ltd. (TSX VENTURE: VXL) announced plans to complete a non-brokered private placement offering of up to 2,456,140 units at $0.1425 per unit to raise gross proceeds of up to $350,000.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional shares at $0.19 per share for five years following the offering's closure.

The company expects to close the offering on or around November 14, 2025, subject to TSX Venture Exchange approval and other conditions.

Vaxil will pay finders a cash commission of up to 8% of gross proceeds and issue finders' warrants equal to